Avid Bioservices Inc (CDMO)

[senrex]

I feel that because the MOA of Bavituximab is to stimulate the immune system, and that this does not necessarily occur overnight, that fast growing cancers may not be the best candidates for us in trials designed to "Knock our Socks off!"

I think the immuno-effecting aspect of this drug may well be the characteristic we all remember in the end.